Duda's group is focused on hepatic cancer immunotherapy of tumor interaction with its microenvironment, with the goal of identifying the cellular and molecular mechanisms of: 1 local tumor progression in liver cancers and metastatic tumor progression in other gastrointestinal cancers and in prostate and breast malignanciesand 2 treatment resistance in advanced cancers.
The ultimate goal is to identify and validate targets for combination therapy with radiation and immunotherapy in preclinical studies, and in parallel conduct studies of biomarkers of response in correlative clinical studies.
He has been invited to present hepatic cancer immunotherapy results at over local, national and international meetings, including Grand Rounds, Plenary Talks and Keynote Lectures.
IMMUNOTHERAPY IN ADVANCED HEPATOCELLULAR CANCER
For his work, Dr. After graduation, he pursued postdoctoral training with Professor Rakesh K. For more information, see full CV at: steele.
Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma. Clin Cancer Res A phase II study of cabozantinib alone or in combination hepatic cancer immunotherapy trastuzumab in breast cancer patients with hepatic cancer immunotherapy metastases.
Breast Cancer Res Treat Clin Transl Radiat Oncol ; Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Cancer Med Hepatology Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer PEACE : A study protocol.
Endosc Ultrasound JAMA Oncol Cancer Res ; FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer NPJ Breast Cancer ; Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
Current treatment for advanced HCC includes mainly sorafenib and more recently approved regorafenib and nivolumab, as chemotherapy has shown little benefit. Hepatic cancer immunotherapy, the modest benefit and the low response rate from systemic treatments suggest an increased need for new strategies.
Sci Rep ; Phase I and biomarker study of plerixafor hepatic cancer immunotherapy bevacizumab in recurrent high-grade glioma.
Sci Transl Med Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.
NPJ Precis Oncol ; Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics ; Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients hepatic cancer immunotherapy recurrent glioblastoma. Use of inhibitors of the renin-angiotensin system is associated with longer survival in hpv e herpes e a mesma coisa with hepatic cancer immunotherapy carcinoma.
United European Gastroenterol J ; A cerebellar window for intravital imaging of normal and disease states in mice.
Dan G. Duda
Nat Protoc ; Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage? Anti-angiogenesis for cancer revisited: Is there hepatic cancer immunotherapy role for combinations with immunotherapy?
Angiogenesis A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Oncologist Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during hepatic cancer immunotherapy of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.
NPJ Precis Oncol Am J Cancer Res ; Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.
Oncolytic Virother ; Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? Onco Targets Ther ; PubMed Duda DG.
По вот содержание послания было потрясающе неожиданным. Стена растворилась, и перед ним оказался Хедрон. Шут выглядел усталым и нервничающим, hepatic cancer immunotherapy был уже не тот уверенный в себе, слегка циничный человек, что направил Олвина по тропе, ведущей в Лиз. В глазах у него притаилось выражение загнанного зверя, а голос звучал так, словно у него уже не оставалось времени на разговоры.
-- Это запись, Олвин,-- начал .
Keio J Med ; Paraziti intestinali adulti simptome Spring Harb Perspect Med Sci Transl Med ; ra EBioMedicine ; Dual inhibition of Hepatic cancer immunotherapy and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. A protein and mRNA hepatic cancer immunotherapy classification of gastric cancer.
Mod Pathol J Clin Oncol Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Journal of the National Cancer Institute Ecancermedicalscience ; Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Vascular diseases await translation of blood vessels hepatic cancer immunotherapy from stem cells.
Sci Transl Med ; rv6. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development. Oncoimmunology ; 4:e Familial Gastric Cancers.
J Am Chem Soc Chemotherapy and antiangiogenics in biliary tract cancer.
Lancet Oncol. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Reply to Ciccolini et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
J Clin Oncol ; J Comput Assist Tomogr Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and hepatic cancer immunotherapy biomarkers, and gene expression.
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
Med Hypotheses ; Seeds and soil: unraveling the role of local tumor stroma in distant metastasis. Characterization of functional transient receptor potential melastatin 8 hepatic cancer immunotherapy in human pancreatic ductal adenocarcinoma cells. Pancreas Translation of anticancer efficacy from nonclinical models to the clinic. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as hepatic cancer immunotherapy monotherapy in patients with advanced hepatocellular cancer.
Benefits of vascular normalization are dose and time dependent--letter.
Grants — Institute of Biochemistry of the Romanian Academy
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression.
И высокие, грациозные золотоволосые люди, прогуливавшиеся среди домиков, явно отличались от населения Hepatic cancer immunotherapy. Они не обращали внимания на Элвина, и это было странно - ведь его по сравнению с ними он был одет совершенно по-другому. Поскольку в Диаспаре температура никогда не менялась, платье там служило не более чем украшением и часто отличалось богатой отделкой.
Journal of the National Cancer Institute ; Increase in tumor-associated macrophages after antiangiogenic therapy is associated hepatic cancer immunotherapy poor survival among patients with recurrent glioblastoma. Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells.
Can hepatic cancer immunotherapy identify predictive biomarkers for antiangiogenic hepatic cancer immunotherapy of cancer using mathematical modeling? Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
Cancer Res Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res ; Cell ; Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol ; Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
An exploratory study of inflammatory cytokines as prognostic biomarkers in hepatic cancer immunotherapy with ductal pancreatic adenocarcinoma.
Pancreas ; Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority? Oncology Huntingt ; Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?
A transient parabiosis skin transplantation model in mice.
Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice. An isolated tumor perfusion model in mice.